The management of acute coronary syndromes involves multiple pharmacological and interventional options, highlighting the need to identify specific patient subgroups for targeted therapy.
This paper reviews the multiple treatment options available for acute coronary syndromes and highlights the challenge of identifying specific patient subgroups for tailored therapy.
The acute coronary syndromes, which comprise unstable angina, myocardial infarction without ST-segment elevation, and myocardial infarction with ST-segment elevation, continue to be a major health problem. Recent important advances in revascularization techniques, such as the advent of coronary-artery stenting, have been paralleled by developments in drug treatment. A typical approach to the acute coronary syndromes includes multiple treatment options: aspirin, beta-blockers, nitrates, unfractionated heparin, low-molecular-weight heparin, intravenous glycoprotein IIb/IIIa receptor inhibitors, clopidogrel, coronary stenting, thrombolytic agents, statins, and angiotensin-converting–enzyme (ACE) inhibitors. Therefore, one of the most important challenges in this era of cost containment is to identify the subgroup of . . .
LeRoy E. Rabbani (2001) conducted a review in Acute Coronary Syndromes. The management of acute coronary syndromes involves multiple pharmacological and interventional options, highlighting the need to identify specific patient subgroups for targeted therapy.